Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Verastem, Inc. (VSTM)

1.2   0.05 (4.35%) 06-29 18:23
Open: 1.14 Pre. Close: 1.15
High: 1.215 Low: 1.12
Volume: 1,022,947 Market Cap: 224(M)
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.22 - 1.22 1.22 - 1.23
Low: 1.11 - 1.11 1.11 - 1.12
Close: 1.19 - 1.2 1.2 - 1.21

Technical analysis

as of: 2022-06-29 4:58:33 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.5     One year: 1.71
Support: Support1: 1    Support2: 0.83
Resistance: Resistance1: 1.29    Resistance2: 1.47
Pivot: 1.14
Moving Average: MA(5): 1.21     MA(20): 1.19
MA(100): 1.3     MA(250): 2.09
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 41     %D(3): 45.1
RSI: RSI(14): 49.8
52-week: High: 3.81  Low: 1
Average Vol(K): 3-Month: 2,557 (K)  10-Days: 3,970 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ VSTM ] has closed below upper band by 31.6%. Bollinger Bands are 30.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 29 Jun 2022
Verastem Stock: Looking Increasingly Attractive (NASDAQ:VSTM) - Seeking Alpha

Thu, 23 Jun 2022
3 Top Penny Stocks to Add to Your July 2022 Watchlist - Miami County Republic

Fri, 17 Jun 2022
Verastem Inc (VSTM) Stock Falls -6.78% This Week: Is It a Good Pick? - InvestorsObserver

Mon, 06 Jun 2022
Verastem VS-6766 shows promise in phase 2 ovarian cancer study - Seeking Alpha

Sun, 05 Jun 2022
Verastem, Inc. (NASDAQ:VSTM) Expected to Announce Earnings of -$0.10 Per Share - MarketBeat

Sat, 14 May 2022
Verastem (NASDAQ:VSTM) Lowered to Sell at - Defense World

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 182 (M)
% Held by Insiders 1.4281e+008 (%)
% Held by Institutions 0.9 (%)
Shares Short 6,430 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -6.265e+007
EPS Est Next Qtl -0.38
EPS Est This Year -1.38
EPS Est Next Year -1.54
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -10
Return on Assets (ttm) 372.2
Return on Equity (ttm) -29.9
Qtrly Rev. Growth 606000
Gross Profit (p.s.) -106.39
Sales Per Share -74.7
EBITDA (p.s.) 644681
Qtrly Earnings Growth -0.5
Operating Cash Flow 0 (M)
Levered Free Cash Flow -54 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -1.7
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 2.16

Stock Dividends

Dividend 0
Forward Dividend 7.37e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.